close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Coverage Overview

Although SYNVISC® is eligible for reimbursement by most insurance carriers, benefits vary widely across insurers, in accordance with each patient's specific employer-contracted benefits.

Click on the links below for an overview of third-party payers' policies regarding SYNVISC coverage:

  • Private Insurance—Understand coverage guidelines related to purchase, billing, and administration of SYNVISC.
  • Medicare—Explore in-office purchase and billing requirements, plus the Competitive Acquisition Program (CAP) guidelines.
  • Medicaid—Ask the right questions about your state's coverage criteria.
  • VA/DOD—Learn about coverage for benefits offered through the Veterans Administration and Department of Defense (TRICARE).

Do you have questions about insurance coverage, filing claims, or billing?
Check with specific patient insurance carriers or call SYNVISC ConnectionSM at
1-800-982-8292, M-F, 9am-6pm (EST).

Providers retain responsibility for determining reimbursement and insurance issues related to their patients. Genzyme cannot be responsible for failure of a provider to obtain reimbursement.




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)